



Supplementary Material

Supplemental Figure 1



Supplementary Figure 1. Mortality and body weight changes during long-term administration of 1 mg/kg doses of adalimumab and ozoralizumab. **(A)** Survival rates of the Tg197 mice in the *in vivo* long-term efficacy study. The percent survival rates of animals injected with antibody or vehicle twice weekly starting at 3 weeks of age were: vehicle-treated group = 80% (euthanized at week 11), 1 mg/kg adalimumab group = 50% (euthanized at week 16), and 1 mg/kg ozoralizumab-treated group = 100% (euthanized at week 16). Survival curves were compared using the log-rank test. **(B)** Changes in body weight at the time periods indicated. Results are expressed as the mean \pm SEM ($n = 5-10$).

Supplemental Figure 2



Supplementary Figure 2. Changes in body weight of the Tg197 mice during administration of adalimumab or ozoralizumab in the second study. Body weights were monitored weekly from 3 weeks of age to 11 or 12 weeks of age. Results are expressed as the mean \pm SEM (n = 10–32).